Literature DB >> 22425562

Histone deacetylase inhibitors block IFNγ-induced STAT1 phosphorylation.

Torsten Ginter1, Carolin Bier, Shirley K Knauer, Kalsoom Sughra, Dagmar Hildebrand, Tobias Münz, Theresa Liebe, Regine Heller, Andreas Henke, Roland H Stauber, Werner Reichardt, Johannes A Schmid, Katharina F Kubatzky, Thorsten Heinzel, Oliver H Krämer.   

Abstract

Signal transducer and activator of transcription 1 (STAT1) is important for innate and adaptive immunity. Histone deacetylase inhibitors (HDACi) antagonize unbalanced immune functions causing chronic inflammation and cancer. Phosphorylation and acetylation regulate STAT1 and different IFNs induce phosphorylated STAT1 homo-/heterodimers, e.g. IFNα activates several STATs whereas IFNγ only induces phosphorylated STAT1 homodimers. In transformed cells HDACi trigger STAT1 acetylation linked to dephosphorylation by the phosphatase TCP45. It is unclear whether acetylation differentially affects STAT1 activated by IFNα or IFNγ, and if cellular responses to both cytokines depend on a phosphatase-dependent inactivation of acetylated STAT1. Here, we report that HDACi counteract IFN-induced phosphorylation of a critical tyrosine residue in the STAT1 C-terminus in primary cells and hematopoietic cells. STAT1 mutants mimicking a functionally inactive DNA binding domain (DBD) reveal that the number of acetylation-mimicking sites in STAT1 determines whether STAT1 is recruited to response elements after stimulation with IFNγ. Furthermore, we show that IFNα-induced STAT1 heterodimers carrying STAT1 molecules mimicking acetylation bind cognate DNA and provide innate anti-viral immunity. IFNγ-induced acetylated STAT1 homodimers are though inactive, suggesting that heterodimerization and complex formation can rescue STAT1 lacking a functional DBD. Apparently, the type of cytokine determines how acetylation affects the nuclear entry and DNA binding of STAT1. Our data contribute to a better understanding of STAT1 regulation by acetylation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425562     DOI: 10.1016/j.cellsig.2012.02.018

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  15 in total

1.  HDAC inhibitor-mediated beta-cell protection against cytokine-induced toxicity is STAT1 Tyr701 phosphorylation independent.

Authors:  Mattias S Dahllöf; Dan P Christensen; Mette Harving; Bridget K Wagner; Thomas Mandrup-Poulsen; Morten Lundh
Journal:  J Interferon Cytokine Res       Date:  2014-07-25       Impact factor: 2.607

2.  Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block.

Authors:  Robert M Clancy; Androo J Markham; Joanne H Reed; Miroslav Blumenberg; Marc K Halushka; Jill P Buyon
Journal:  J Autoimmun       Date:  2015-10-01       Impact factor: 7.094

3.  Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms.

Authors:  Xiaohua Pan; Xin Fang; Fei Wang; Hongli Li; Wenying Niu; Wenjie Liang; Chengfei Wu; Jiahong Li; Xing Tu; Li-Long Pan; Jia Sun
Journal:  Br J Pharmacol       Date:  2019-12-08       Impact factor: 8.739

4.  Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses.

Authors:  Ewa M Kosciuczuk; Swarna Mehrotra; Diana Saleiro; Barbara Kroczynska; Beata Majchrzak-Kita; Pawel Lisowski; Caroline Driehaus; Anna Rogalska; Acara Turner; Thomas Lienhoop; David Gius; Eleanor N Fish; Athanassios Vassilopoulos; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

5.  Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis.

Authors:  Osamu Hirata; Satoshi Okada; Miyuki Tsumura; Reiko Kagawa; Mizuka Miki; Hiroshi Kawaguchi; Kazuhiro Nakamura; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Yoshihiro Takihara; Masao Kobayashi
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Acetylation and sumoylation control STAT5 activation antagonistically.

Authors:  Oliver H Krämer; Richard Moriggl
Journal:  JAKSTAT       Date:  2012-07-01

7.  Caspase-3 and caspase-6 cleave STAT1 in leukemic cells.

Authors:  Verena Licht; Katrin Noack; Bernhard Schlott; Martin Förster; Yvonne Schlenker; Andreas Licht; Oliver H Krämer; Thorsten Heinzel
Journal:  Oncotarget       Date:  2014-04-30

8.  SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells.

Authors:  Sylvia Müller; Yuan Chen; Torsten Ginter; Claudia Schäfer; Marc Buchwald; Lienhard M Schmitz; Jana Klitzsch; Alexander Schütz; Andrea Haitel; Katharina Schmid; Richard Moriggl; Lukas Kenner; Karlheinz Friedrich; Claude Haan; Iver Petersen; Thorsten Heinzel; Oliver H Krämer
Journal:  Oncotarget       Date:  2014-05-30

9.  The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Authors:  Harini Nivarthi; Claire Gordziel; Madeleine Themanns; Nina Kramer; Markus Eberl; Björn Rabe; Michaela Schlederer; Stefan Rose-John; Thomas Knösel; Lukas Kenner; Patricia Freund; Fritz Aberger; Xiaonan Han; Robert Kralovics; Helmut Dolznig; Susanne Jennek; Karlheinz Friedrich; Richard Moriggl
Journal:  Oncotarget       Date:  2016-08-09

10.  Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.

Authors:  Pengfei Xu; Wei Xiong; Yun Lin; Liping Fan; Hongchao Pan; Yaochen Li
Journal:  Cell Death Dis       Date:  2021-08-07       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.